Recruiting NCT07669623
Effects of Different Acupuncture Techniques on the Success Rate in Patients With Recurrent Implantation Failure
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Placebo Group, acupuncture group 1, acupuncture group 2.
- Who it may be relevant to
- Registry conditions: Implantation Failure. Basic parameters: 20 years — 40 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
To conduct a multi-center, randomized, controlled clinical study aimed at formally evaluating the impact of different acupuncture methods on the success rate in patients with recurrent implantation failure
Interventions
- Device Placebo Group
nonpenetrating placebo needles - Device acupuncture group 1
indwelling intradermal needles - Device acupuncture group 2
combining fire needle and regular acupuncture
Primary outcome measures
- clinical pregnancy [Time frame: 2 years]
Secondary outcome measures (2)
- β-hCG-positive pregnancy [Time frame: 2 years]
- live birth [Time frame: 3 years]
Eligibility criteria
Inclusion criteria
- Meets the criteria for RIF diagnosis (≥ 2 instances of unsuccessful transfer of high-quality embryos).
- Age: 20 to 40 years old.
- Planning for a cycle involving the transfer of frozen-thawed embryos (FET).
- Possession of a transplantable D3 frozen embryo (≥6 cells) or a frozen blastocyst (≥3BC).
- Estradiol-progesterone replacement therapy: endometrial thickness ≥ 7 mm within the period of endometrial transformation.
Exclusion criteria
- Individuals planning to undergo preimplantation genetic diagnosis (PGD).
- Recipients of egg donations.
- Chromosomal abnormalities in either spouse or one partner (excluding chromosomal polymorphisms).
- Patients with known embryo-related factors leading to implantation failure.
- Abnormalities of the uterus that may affect implantation (including uterine malformations, uterine tuberculosis, submucosal myomas, severe uterine adhesions, severe uterine endometriosis, myomas with a diameter of ≥4 cm, and so on).
- Abnormalities in immunity and blood coagulation
- Recurrent spontaneous abortions (loss of a fetus before 28 weeks of gestation occurring twice or more).
- Individuals with other endocrine disorders, such as thyroid disorders, hyperprolactinemia, insulin resistance, diabetes, and adrenal disorders, whose hormone levels have not been well-controlled over the past 3 months.
- Individuals with untreated hydrosalpinx;
- Individuals with a Body Mass Index (BMI) below 18 and above 25 kg/ m2.
- Men with severe abnormalities in semen quality.
- Individuals with a history of needle phobia.
- Individuals who have previously participated in this study or received acupuncture treatment within the past three months;
- Any other conditions deemed unsuitable for participation by the researchers.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- Tongji Hospital,Tongji medical college,HUST — Wuhan
Identifiers
NCT: NCT07669623 · TJ-IRB202605092